<DOC>
	<DOCNO>NCT00816829</DOCNO>
	<brief_summary>Objectives : investigate potential effect fenofibrate symptom biological change associate sleep apnea syndrome .</brief_summary>
	<brief_title>Effect Fenofibrate Sleep Apnea Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<criteria>Having previous diagnosis sleep apnea treat Continuous Positive Airway Pressure ( CPAP ) present clinical symptom sleep apnea Overweight obese , BMI &gt; = 25 kg/m² &lt; 40 kg/m² . Known moderate hypertriglyceridemia , fast Triglycerides level &gt; = 2.0 &lt; 6.0 mmol/L within 3 month inclusion . indication immediate CPAP know endocrine disease , except treat adequately controlled hypothyroidism renal failure plasma creatinine level &gt; 130 µmol/L current chronic liver disease ALanine Amino Transferase ( ALT ) &gt; 2 time upper normal limit ( UNL ) symptomatic gallbladder disease know muscular disease creatine phosphokinase ( CK ) &gt; 3 time UNL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Dyslipidemia</keyword>
	<keyword>Sleep Apnea Syndromes</keyword>
	<keyword>Fenofibrate</keyword>
	<keyword>Obese</keyword>
	<keyword>Overweight obese patient</keyword>
</DOC>